How can you use digital twins for faster clinical trials requiring fewer patients?

Dr Charles Fisher is the CEO and Founder of Unlearn.ai — which uses digital twins to reduce the number of patients required in clinical trials.

In a clinical trial, you usually have a treatment group who receive the drug/treatment, and a control group who receive a placebo. This means that a large number of patients need to be given a placebo — a fake or dummy version of the treatment with no therapeutic effect.

But using generative machine learning models, you can create a digital twin — a digital copy of a patient which might be able to emulate what would have happened to that patient if they’d received a placebo.

The promise of this technology is faster clinical trials, requiring fewer patients and producing better evidence.

Charles completed his PhD in Biophysics at Harvard and has raised $17M to date for Unlearn.ai. We talk about digital twins, viewing clinical trials with a biophysics lens and some of the challenges in getting this technology adopted.

I hope you enjoy.

You can find me on Twitter @MustafaSultan and subscribe to my newsletter on www.musty.io

#052 Digital Twins in Clinical Trials — Dr Charles Fisher (CEO Unlearn.ai)